NIVOCASAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H22FN3O5
Molecular Weight	415.4149
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)[C@]1(CC(=NO1)C2=NC=CC3=C2C=CC=C3)C(=O)N[C@H]4CC(=O)O[C@]4(O)CF

InChI

InChIKey=VYFGDLGHHBUDTQ-ZLGUVYLKSA-N

InChI=1S/C21H22FN3O5/c1-12(2)20(19(27)24-16-9-17(26)29-21(16,28)11-22)10-15(25-30-20)18-14-6-4-3-5-13(14)7-8-23-18/h3-8,12,16,28H,9-11H2,1-2H3,(H,24,27)/t16-,20+,21+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H22FN3O5
Molecular Weight	415.4149
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22006541 | http://adisinsight.springer.com/drugs/800021460 |

Nivocasan (aka GS-9450) was discovered by LG Life Sciences and developed by Gilead Sciences. Nivocasan is an irreversible inhibitor of caspase 1, 8, and 9, and therefore able to prevent apoptosis. Nivocasan has been investigated as a treatment option for Hepatic fibrosis and Non-alcoholic steatohepatitis related to Hepatitis C infection. It had advanced to Phase II clinical trials before the development program was suspended.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Caspase-1 5 Target ID: P29466 Gene ID: 834.0 Gene Symbol: CASP1 Target Organism: Homo sapiens (Human) Sources: http://europepmc.org/abstract/MED/21667042	Inhibitor 8297
Caspase-8 2 Target ID: Q14790\|\|\|Q15780\|\|\|Q96T22 Gene ID: 841.0 Gene Symbol: CASP8 Target Organism: Homo sapiens (Human) Sources: http://europepmc.org/abstract/MED/21667042	Inhibitor 8297
Caspase-9 5 Target ID: P55211\|\|\|Q9UEQ3 Gene ID: 842.0 Gene Symbol: CASP9 Target Organism: Homo sapiens (Human) Sources: http://europepmc.org/abstract/MED/21667042	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic hepatitis C 42 Sources: http://europepmc.org/abstract/MED/21667042	Primary		Phase II 1132	Unknown Approved Use Unknown
Nonalcoholic steatohepatitis 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22006541	Primary		Phase II 1132	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
BLD Pharm	BD01175545	http://www.bldpharm.com/products/908253-63-4.html
Chemieliva Pharmaceutical Co., Ltd	PBCM1460438
MuseChem	I008307	https://www.musechem.com/product/I008307.html
Smolecule	S549030	http://www.smolecule.com/products/s549030
THE BioTek	bt-287303	https://www.thebiotek.com/product/inhibitors/bt-287303
eNovation Chemicals	D673437	https://www.enovationchem.com/ProductDetails.asp?ProductID=D673437

PubMed

Title	Date	PubMed
Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats.	2013 Dec	24045874

Patents

Sample Use Guides

In Vivo Use Guide

Patients with Human Chronic Hepatitis C virus (HCV) and suffering from nonalcoholic steatohepatitis (NASH) were administered up to 40 mg of Nivocasan orally once daily for 4 weeks followed by a four week period with no dosing.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:47:04 GMT 2023` Edited by `admin` on `Fri Dec 15 19:47:04 GMT 2023`
Record UNII	9554OW6MVU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NIVOCASAN

Official Name

English

LB84451

Code

English

nivocasan [INN]

Common Name

English

NIVOCASAN [USAN]

Common Name

English

5-ISOXAZOLECARBOXAMIDE, N-((2S,3S)-2-(FLUOROMETHYL)TETRAHYDRO-2-HYDROXY-5-OXO-3- FURANYL)-4,5-DIHYDRO-3-(1-ISOQUINOLINYL)-5-(1-METHYLETHYL)-, (5R)-

Common Name

English

(5R)-N-((2S,3S)-2-(FLUOROMETHYL)-2-HYDROXY-5-OXO-TETRAHYDROFURAN-3-YL)-3-(ISOQUINOLIN- 1-YL)-5-(1-METHYLETHYL)-4,5-DIHYDROISOXAZOLE-5-CARBOXAMIDE

Systematic Name

English

LB-84451

Code

English

Nivocasan [WHO-DD]

Common Name

English

GS-9450

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C471